Pulmonx Corporation is a commercial-stage medical technology company. The Company provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.
Código da empresaLUNG
Nome da EmpresaPulmonx Corp
Data de listagemOct 01, 2020
CEOFrench (Glendon E)
Número de funcionários291
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 01
Endereço700 Chesapeake Dr
CidadeREDWOOD CITY
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94063
Telefone16509342600
Sitehttps://pulmonx.com/
Código da empresaLUNG
Data de listagemOct 01, 2020
CEOFrench (Glendon E)
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados